Related Experiment Video
Updated: Jul 2, 2025

The Intra-Aortic Balloon Pump
Published on: February 5, 2021
Clinical Implications of Ivabradine in the Contemporary Era
1The Second Department of Internal Medicine, University of Toyama, Toyama 930-8555, Japan.
Insights
Ivabradine, an If ion channel inhibitor, effectively reduces heart rate in heart failure patients. Echocardiography-guided therapy optimizes its use, improving cardiac remodeling and patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Background:
- Ivabradine inhibits the If ion channel, lowering heart rate while maintaining hemodynamic stability.
- Current indication: heart failure with reduced ejection fraction refractory to beta-blockers.
- Aggressive up-titration of ivabradine optimizes heart rate control and facilitates beta-blocker titration.
Purpose of the Study:
- To introduce and explain the novel overlap theory for optimizing ivabradine therapy.
- To explore the application of echocardiography-guided ivabradine therapy for improved patient outcomes.
- To discuss the potential expansion of ivabradine's clinical indications.
Main Methods:
- Utilizing trans-mitral Doppler echocardiography to assess E-wave and A-wave overlap.
- Implementing echocardiography-guided ivabradine therapy to minimize E-wave and A-wave overlap.
- Reviewing existing literature on ivabradine's efficacy and potential new applications.
Main Results:
- Optimal heart rate, identified by minimal E-wave and A-wave overlap, confers substantial benefits.
- Echocardiography-guided ivabradine therapy promotes superior cardiac reverse remodeling.
- This approach leads to more favorable clinical outcomes compared to standard care.
Conclusions:
- Echocardiography-guided ivabradine therapy, based on the overlap theory, enhances cardiac reverse remodeling and clinical outcomes.
- Ivabradine may not benefit patients with heart failure with preserved ejection fraction, acute heart failure, sepsis, or stable angina.
- Further investigation is needed for ivabradine's applicability in atrial fibrillation.
Abstract:
Ivabradine is a recently introduced inhibitor of the If ion channel, which exhibits the capacity to reduce heart rate while preserving hemodynamic stability. At present, ivabradine finds its clinical indication in patients suffering from heart failure with reduced ejection fraction and maintaining a relative sinus rhythm refractory to beta-blockers. To optimize heart rate control, it is recommended to pursue an aggressive up-titration of ivabradine. This approach may ameliorate tachycardia-induced hypotension by incrementally enhancing cardiac output and allow further up-titration of agents aimed at ameliorating heart failure, such as beta-blockers. Both the modulation of heart rate itself and the up-titration of agents targeting heart failure lead to cardiac reverse remodeling, consequently culminating in a subsequent reduction in mortality and morbidity. A novel overlap theory that our team proposed recently has emerged in recent times. Under trans-mitral Doppler echocardiography, the E-wave and A-wave closely juxtapose one another without any overlapping at the optimal heart rate. Employing echocardiography-guided ivabradine for heart-rate modulation to minimize the overlap between the E-wave and A-wave appears to confer substantial benefits to patients with heart failure. This approach facilitates superior cardiac reverse remodeling and yields more favorable clinical outcomes when compared to those patients who do not receive echocardiography-guided care. The next pertinent issue revolves around the potential expansion of ivabradine's clinical indications to encompass a broader spectrum of diseases. It is imperative to acknowledge that ivabradine may not yield clinically significant benefits in patients afflicted by heart failure with preserved ejection fraction, acute heart failure, sepsis, or stable angina. An important fact yet to be explored is the clinical applicability of ivabradine in patients with atrial fibrillation, a concern that beckons future investigation. In this review, the concept of overlap theory it introduced, along with its application to expand the indication of ivabradine and the overlap theory-guided optimal ivabradine therapy.
More Related Videos
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: Inotropic Agents